DJIA 18,132.70 -81.72 -0.45%
NASDAQ 4,963.53 -24.36 -0.49%
S&P 500 2,104.50 -6.24 -0.30%
market minute promo


company name or ticker

Forget Pills! Could This Device Put an End to Obesity in America?

We've witnessed three oral anti-obesity meds approved since mid-2012, but this newly approved device could be a game-changer.

5 Obesity Stocks Investors Are Watching

Vivus Gets New 10% Stakeholder: What To Watch For

Orexigen's Contrave May Have Pricing Competition

Why VIVUS, Inc. Stock Descended 14% in December

Instead of shrinking waistlines, VIVUS shareholders saw their shares shrink in value by 14% in December. Find out what troubled VIVUS in December and whether or not this dip represents a buying opportunity.

History Suggests MannKind Corporation's Afrezza Could Already Be Doomed

Afrezza could be a game-changing inhaled diabetes therapy, but it must overcome an obstacle that crushed previous potential game changers.

Arena Pharmaceuticals Inc.'s Phase 1 Data is Worth $550 Million!?

Investors bid up Arena Pharmaceuticals 76% after the biotech releases positive phase 1 data for APD334.

Why Arena Pharmaceuticals, Inc. Stock Slumped 17% in December

Arena Pharmaceuticals stock took a tumble in December after a rival receives good news in the EU. Find out whether this dip is a buying opportunity or a red flag to keep your distance.

Anticipated FDA Approval Eludes Enteromedics

The 52-Week Low Club for Tuesday

See More Articles...